Graduate School of Life Sciences
Refine
Has Fulltext
- yes (104)
Is part of the Bibliography
- yes (104)
Year of publication
- 2022 (104) (remove)
Document Type
- Doctoral Thesis (101)
- Journal article (2)
- Book (1)
Keywords
- Angststörung (3)
- DNA damage (3)
- GPCR (3)
- Jugend (3)
- Kind (3)
- T-Lymphozyt (3)
- Tissue Engineering (3)
- Transcription (3)
- 3D-Druck (2)
- Angst (2)
Institute
- Graduate School of Life Sciences (104)
- Institut für Virologie und Immunbiologie (6)
- Theodor-Boveri-Institut für Biowissenschaften (6)
- Institut für Klinische Epidemiologie und Biometrie (5)
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (5)
- Medizinische Fakultät (5)
- Medizinische Klinik und Poliklinik II (5)
- Institut für Psychologie (4)
- Abteilung für Funktionswerkstoffe der Medizin und der Zahnheilkunde (3)
- Institut für Klinische Neurobiologie (3)
Sonstige beteiligte Institutionen
- Helmholtz Institute for RNA-based Infection Research (HIRI) (2)
- Department of Cellular Therapies, University of Navarra, Pamplona, Spain (1)
- Department of X-ray Microscopy, University of Würzburg, Würzburg, Germany (1)
- Interdisziplinäre Zentrum für Klinische Forschung (IZKF) (1)
- Politecnico di Milano (1)
- Translationale soziale Neurowissenschaften (1)
- Universitätsklinikum Würzburg (UKW) (1)
- Zentrum für Interdisziplinäre Medizin der Uni Würzburg (1)
Protocadherins (PCDHs) belong to the cadherin superfamily and represent the largest subgroup of calcium-dependent adhesion molecules. In the genome, most PCDHs are arranged in three clusters, α, β, and γ on chromosome 5q31. PCDHs are highly expressed in the central nervous system (CNS). Several PCDHs have tumor suppressor functions, but their individual role in primary brain tumors has not yet been elucidated. Here, we examined the mRNA expression of PCDHGC3, a member of the PCDHγ cluster, in non-cancerous brain tissue and in gliomas of different World Health Organization (WHO) grades and correlated it with the clinical data of the patients. We generated a PCDHGC3 knockout U343 cell line and examined its growth rate and migration in a wound healing assay. We showed that PCDHGC3 mRNA and protein were significantly overexpressed in glioma tissue compared to a non-cancerous brain specimen. This could be confirmed in glioma cell lines. High PCDHGC3 mRNA expression correlated with longer progression-free survival (PFS) in glioma patients. PCDHGC3 knockout in U343 resulted in a slower growth rate but a significantly faster migration rate in the wound healing assay and decreased the expression of several genes involved in WNT signaling. PCDHGC3 expression should therefore be further investigated as a PFS-marker in gliomas. However, more studies are needed to elucidate the molecular mechanisms underlying the PCDHGC3 effects.
Tumor necrosis factor (TNF) receptor-2 (TNFR2) has attracted considerable interest as a target for immunotherapy. Indeed, using oligomeric fusion proteins of single chain-encoded TNFR2-specific TNF mutants (scTNF80), expansion of regulatory T cells and therapeutic activity could be demonstrated in various autoinflammatory diseases, including graft-versus-host disease (GvHD), experimental autoimmune encephalomyelitis (EAE) and collagen-induced arthritis (CIA). With the aim to improve the in vivo availability of TNFR2-specific TNF fusion proteins, we used here the neonatal Fc receptor (FcRn)-interacting IgG1 molecule as an oligomerizing building block and generated a new TNFR2 agonist with improved serum retention and superior in vivo activity.
Methods
Single-chain encoded murine TNF80 trimers (sc(mu)TNF80) were fused to the C-terminus of an in mice irrelevant IgG1 molecule carrying the N297A mutation which avoids/minimizes interaction with Fcγ-receptors (FcγRs). The fusion protein obtained (irrIgG1(N297A)-sc(mu)TNF80), termed NewSTAR2 (New selective TNF-based agonist of TNF receptor 2), was analyzed with respect to activity, productivity, serum retention and in vitro and in vivo activity. STAR2 (TNC-sc(mu)TNF80 or selective TNF-based agonist of TNF receptor 2), a well-established highly active nonameric TNFR2-specific variant, served as benchmark. NewSTAR2 was assessed in various in vitro and in vivo systems.
Results
STAR2 (TNC-sc(mu)TNF80) and NewSTAR2 (irrIgG1(N297A)-sc(mu)TNF80) revealed comparable in vitro activity. The novel domain architecture of NewSTAR2 significantly improved serum retention compared to STAR2, which correlated with efficient binding to FcRn. A single injection of NewSTAR2 enhanced regulatory T cell (Treg) suppressive activity and increased Treg numbers by > 300% in vivo 5 days after treatment. Treg numbers remained as high as 200% for about 10 days. Furthermore, a single in vivo treatment with NewSTAR2 upregulated the adenosine-regulating ectoenzyme CD39 and other activation markers on Tregs. TNFR2-stimulated Tregs proved to be more suppressive than unstimulated Tregs, reducing conventional T cell (Tcon) proliferation and expression of activation markers in vitro. Finally, singular preemptive NewSTAR2 administration five days before allogeneic hematopoietic cell transplantation (allo-HCT) protected mice from acute GvHD.
Conclusions
NewSTAR2 represents a next generation ligand-based TNFR2 agonist, which is efficiently produced, exhibits improved pharmacokinetic properties and high serum retention with superior in vivo activity exerting powerful protective effects against acute GvHD.
Schimmelpilze können in Abhängigkeit des Immunstatus und der Vorerkrankungen betroffener Patienten unterschiedliche Krankheitsbilder wie Hypersensitivitäts-erkrankungen oder lebensbedrohliche invasive Infektionen hervorrufen. Da die Diagnosestellung dieser Erkrankungen mitunter komplex und insensitiv ist, sollten im Rahmen dieser Arbeit unterschiedliche Ansätze neuer diagnostischer Assays untersucht werden.
In den letzten Jahren wurden Assays entwickelt, die auf Basis durchflusszytometrisch quantifizierter Pilz-spezifischer T-Zellen aus peripherem Blut einen supportiven Biomarker zur Diagnostik invasiver Mykosen liefern könnten. Da die hierfür isolierten T-Zellen anfällig gegenüber präanalytischer Lagerzeiten und immunsuppressiver Medikation sind, wurden hier Protokolloptimierungen vorgenommen, um anhand eines Vollblut-basierten Assays mit zusätzlicher CD49d-Kostimulation diesen Limitationen entgegen zu wirken. In einer Studie an gesunden Probanden konnte dabei gezeigt werden, dass die Kombination der Durchflusszytometrie mit ausgewählten Zytokin-Messungen (IL-5, IL-10 und IL-17) zu einer verbesserten Erkennung vermehrt Schimmelpilz-exponierter Personen beitragen könnte. Neben Infektionen könnten dabei im umwelt- und arbeitsmedizinischen Kontext Polarisationen der T-Zell-Populationen detektiert werden, welche mit Sensibilisierungen und Hypersensitivität assoziiert werden.
Zusätzlich wurde ein in vitro Transwell® Alveolarmodell zur Simulation pulmonaler Pilzinfektionen für Erreger der Ordnung Mucorales adaptiert, durch Reproduktion wichtiger Merkmale der Pathogenese von Mucormykosen validiert, und für Untersuchungen der Immunpathologie und Erreger-Invasion verwendet. Das Modell wurde anschließend zur in vitro Evaluation von radioaktiv markiertem Amphotericin B mit 99mTc oder 68Ga als nuklearmedizinischen Tracer verwendet. Die untersuchten Schimmelpilze zeigten dabei eine zeit- und dosis-abhängige Aufnahme der Tracer, während bakteriell infizierte Proben nicht detektiert wurden. Die erhobenen Daten dokumentieren ein vielversprechendes Potenzial von Amphotericin B-basierten Tracer, das in zukünftigen in vivo Studien weiter evaluiert werden sollte.
Protein-DNA interactions are central to many biological processes and form the bedrock of gene transcription, DNA replication, and DNA repair processes. Many proteins recognize specific sequences in DNA- a restriction enzyme must only cut at the correct sequence and a transcription factor should bind at its consensus sequence. Some proteins are designed to bind to specific structural or chemical features in DNA, such as DNA repair proteins and some DNA modifying enzymes. Target-specific DNA binding proteins initially bind to non-specific DNA and then search for their target sites through different types of diffusion mechanisms. Atomic force microscopy (AFM) is a single-molecule technique that is specifically well-suited to resolve the distinct states of target-specific as well as nonspecific protein-DNA interactions that are vital for a deeper insight into the target site search mechanisms of these enzymes. In this thesis, protein systems involved in epigenetic regulation, base excision repair (BER), and transcription are investigated by single-molecule AFM analyses complemented by biochemical and biophysical experiments.
The first chapter of this thesis narrates the establishment of a novel, user-unbiased MatLab-based tool for automated DNA bend angle measurements on AFM data. This tool has then been employed to study the initial lesion detection step of several DNA glycosylases. These results promoted a model describing the altered plasticities of DNA at the target lesions of DNA glycosylases as the fundamental mechanism for their enhanced efficiency of lesion detection.
In the second chapter of this thesis, the novel automated tool has been further extended to provide protein binding positions on the DNA along with corresponding DNA bend angles and applied to the study of DNMT3A DNA methyltransferase. These AFM studies revealed preferential co-methylation at specific, defined distances between two CpG sites by the enzyme and when combined with biochemical analyses and structural modelling supported novel modes of CpG co-methylation by DNMT3A.
In the third chapter of this thesis, the role of 8-oxo-guanine glycosylase (hOGG1) in Myc-mediated transcription initiation has been investigated. AFM analyses revealed that in the presence of oxidative damage in DNA, Myc is recruited to its target site (E-box) by hOGG1 through direct protein-protein interactions, specifically under oxidizing conditions. Intriguingly, oxidation of hOGG1 was further observed to result in dimerization of hOGG1, which may also play a role in the mechanism of transcription regulation by hOGG1 under oxidative stress.
Although the field of fungal infections advanced tremendously, diagnosis of invasive pulmonary aspergillosis (IPA) in immunocompromised patients continues to be a challenge. Since IPA is a multifactorial disease, investigation from different aspects may provide new insights, helpful for improving IPA diagnosis. This work aimed to characterize the human immune response to Aspergillus fumigatus in a multilevel manner to identify characteristic molecular candidates and risk factors indicating IPA, which may in the future support already established diagnostic assays. We combined in vitro studies using myeloid cells infected with A. fumigatus and longitudinal case-control studies investigating patients post allogeneic stem cell transplantation (alloSCT) suffering from IPA and their match controls.
Characteristic miRNA and mRNA signatures indicating A. fumigatus-infected monocyte-derived dendritic cells (moDCs) demonstrated the potential to differentiate between A. fumigatus and Escherichia coli infection. Transcriptome and protein profiling of alloSCT patients suffering from IPA and their matched controls revealed a distinctive IPA signature consisting of MMP1 induction and LGAL2 repression in combination with elevated IL-8 and caspase-3 levels. Both, in vitro and case-control studies, suggested cytokines, matrix-metallopeptidases and galectins are important in the immune response to A. fumigatus. Identified IPA characteristic molecular candidates are involved in numerous processes, thus a combination of these in a distinctive signature may increase the specificity. Finally, low monocyte counts, severe GvHD of the gut (grade ≥ 2) and etanercept administration were significantly associated with IPA diagnosis post alloSCT. Etanercept in monocyte-derived macrophages (MDM) infected with A. fumigatus downregulates genes involved in the NF-κB and TNF-α pathway and affects the secretion of CXCL10.
Taken together, identified characteristic molecular signatures and risk factors indicating IPA may in the future in combination with established fungal biomarkers overcome current diagnostic challenges and help to establish tailored antifungal therapy. Therefore, further multicentre studies are encouraged to evaluate reported findings.
Parkinson’s Disease (PD) constitutes a major healthcare burden in Europe. Accounting for aging alone, ~700,000 PD cases are predicted by 2040. This represents an approximately 56% increase in the PD population between 2005 and 2040, with a consequent rise in annual disease‐related medical costs. Gait and balance disorders are a major problem for patients with PD and their caregivers, mainly because to their correlation with falls. Falls occur as a result of a complex interaction of risk factors. Among them, Freezing of Gait (FoG) is a peculiar gait derangement characterized by a sudden and episodic inability to produce effective stepping, causing falls, mobility restrictions, poor quality of life, and increased morbidity and mortality. Between 50–70% of PD patients have FoG and/or falls after a disease duration of 10 years, only partially and inconsistently improved by dopaminergic treatment and Deep Brain Stimulation (DBS). Treatment-induced worsening has been also observed under certain conditions. Effective treatments for gait disturbances in PD are lacking, probably because of the still poor understanding of the supraspinal locomotor network.
In my thesis, I wanted to expand our knowledge of the supraspinal locomotor network and in particular the contribution of the basal ganglia to the control of locomotion. I believe this is a key step towards new preventive and personalized therapies for postural and gait problems in patients with PD and related disorders. In addition to patients with PD, my studies also included people affected by Progressive Supranuclear Palsy (PSP). PSP is a rare primary progressive parkinsonism characterized at a very early disease stage by poor balance control and frequent backwards falls, thus providing an in vivo model of dysfunctional locomotor control.
I focused my attention on one of the most common motor transitions in daily living, the initiation of gait (GI). GI is an interesting motor task and a relevant paradigm to address balance and gait impairments in patients with movement disorders, as it is associated with FoG and high risk of falls. It combines a preparatory (i.e., the Anticipatory Postural Adjustments [APA]) and execution phase (the stepping) and allows the study of movement scaling and timing as an expression of muscular synergies, which follow precise and online feedback information processing and integration into established feedforward patterns of motor control.
By applying a multimodal approach that combines biomechanical assessments and neuroimaging investigations, my work unveiled the fundamental contribution of striatal dopamine to GI in patients with PD. Results in patients with PSP further supported the fundamental role of the striatum in GI execution, revealing correlations between the metabolic intake of the left caudate nucleus with diverse GI measurements. This study also unveiled the interplay of additional brain areas in the motor control of GI, namely the Thalamus, the Supplementary Motor Area (SMA), and the Cingulate cortex. Involvement of cortical areas was also suggested by the analysis of GI in patients with PD and FoG. Indeed, I found major alterations in the preparatory phase of GI in these patients, possibly resulting from FoG-related deficits of the SMA. Alterations of the weight shifting preceding the stepping phase were also particularly important in PD patients with FoG, thus suggesting specific difficulties in the integration of somatosensory information at a cortical level. Of note, all patients with PD showed preserved movement timing of GI, possibly suggesting preserved and compensatory activity of the cerebellum. Postural abnormalities (i.e., increased trunk and thigh flexion) showed no relationship with GI, ruling out an adaptation of the motor pattern to the altered postural condition. In a group of PD patients implanted with DBS, I further explored the pathophysiological functioning of the locomotor network by analysing the timely activity of the Subthalamic Nucleus (STN) during static and dynamic balance control (i.e., standing and walking). For this study, I used novel DBS devices capable of delivering stimulation and simultaneously recording Local Field Potentials (LFP) of the implanted nucleus months and years after surgery. I showed a gait-related frequency shift in the STN activity of PD patients, possibly conveying cortical (feedforward) and cerebellar (feedback) information to mesencephalic locomotor areas. Based on this result, I identified for each patient a Maximally Informative Frequency (MIF) whose power changes can reliably classify standing and walking conditions. The MIF is a promising input signal for new DBS devices that can monitor LFP power modulations to timely adjust the stimulation delivery based on the ongoing motor task (e.g., gait) performed by the patient (adaptive DBS).
Altogether my achievements allowed to define the role of different cortical and subcortical brain areas in locomotor control, paving the way for a better understanding of the pathophysiological dynamics of the supraspinal locomotor network and the development of tailored therapies for gait disturbances and falls prevention in PD and related disorders.
Der Zusammenhang von neuropathischem Schmerz mit einer gestörten Blut-Nerven-
Schranke (BNS) ist bekannt. Die BNS wird durch Tight Junction Proteine (TJP) gebildet.
Netrin-1 (Ntn1) hat je nach Rezeptorbindung verschiedene Effekte auf TJP und somit auf
die Barriereeigenschaften.
In dieser Arbeit wurde im Tiermodell (Chronic Constriction Injury-CCI) untersucht, ob
Netrin-1 einen Einfluss auf die BNS hat und die Wirkung der Rezeptoren Unc5b und
Neogenin-1 beleuchtet. Es wurde untersucht, ob der barrierestabilisierende Netrin-1-
Spiegel auch von neuropathischen Schmerzen, im Speziellen durch „Chronic Regional
Pain Syndrom“ (CRPS), beeinflusst wird.
Männl. Wistar-Ratten wurde lokal Unc5b Antikörper injeziert oder nach Netrin-1 Gabe
der Neogeninrezeptor durch lokale Neogenin-1-siRNA Injektion geblockt. Die mRNA
Expression von Ntn1, seine Rezeptoren sowie der TJP (Claudine-Cldn) wurde mittels q-
PCR untersucht. Netrin-1 wurde im Rattennerven mittels Western Blot bestimmt. Die
Netrin-1-Spiegel im Plasma von CRPS Patient*innen und Kontrollen wurde mittels ELISA
bestimmt. Im Rattenmodell war die Ntn1 vermehrt exprimiert, die Proteinexpression
mittels Western Blot tendenziell vermindert. Die Claudinexpression war nach CCI
herabreguliert. Netrin-1-Injektion steigerte die Expression von Cldn5 und 19. Der
Netrin-1-Rezeptor UNC5B wird bei Neuropathie verstärkt und Neogenin-1 vermindert
exprimiert. Die Expression von Cldn 12 und Cldn19 war bei Blockade des Unc5b
Rezeptors gesteigert und bei Blockade des Neogenin-1 Rezeptors tendenziell
vermindert. Im Plasma von CRPS Patient*innen zeigte sich ein verminderter Netrin-1-
Spiegel.
Die Ergebnisse der vorliegenden Experimente legen nahe, dass Netrin-1 über die
Stabilisierung der Blut-Nerven-Schranke einen lindernden Effekt auf neuropathische
Schmerzen hat und sich auch die Expression dieses Proteins durch CRPS verändert.
The immune system has the function to defend organisms against a variety of pathogens
and malignancies. To perform this task, different parts of the immune system work in concert and
influence each other to balance and optimize its functional output upon activation. One aspect that
determines this output and ultimately the outcome of the infection is the tissue context in which the
activation takes place. As such, it has been shown that dendritic cells can relay information from
the infection sites to draining lymph nodes. This way, the ensuing adaptive immune response that
is initiated by dendritic cells, is optimized to the tissue context in which the infection needs to be
cleared.
Here, we set out to investigate whether unconventional T cells (UTC) could have a similar
function in directing a site-specific immune response. Using flow cytometry, scRNA-sequencing
and functional assays we demonstrated that UTC indeed drive a characteristic immune response
in lymph nodes depending on the drained tissues. This function of UTC was directly connected to
their lymphatic migration from tissues to draining lymph nodes reminiscent of dendritic cells.
Besides these tissue-derived UTC that migrated via the lymph, we further identified circulatory UTC
that migrated between lymph nodes via the blood. Functional characterization of UTC following
bacterial infection in wt and single TCR-based lineage deficient mice that lacked subgroups of UTC
further revealed that both tissue-derived and circulatory UTC were organized in functional units
independent of their TCR-based lineage-affiliation (MAIT, NKT, gd T cells). Specific reporter mouse
models revealed that UTC within the same functional unit were also located in the same
microanatomical areas of lymph nodes, further supporting their shared function. Our data show that
the numbers and function of UTC were compensated in single TCR-based lineage deficient mice
that lacked subgroups of UTC.
Taken together, our results characterize the transcriptional landscape and migrational
behavior of UTC in different lymph nodes. UTC contribute to a functional heterogeneity of lymph
nodes, which in turn guides optimized, site-specific immune responses. Additionally, we propose
the classification of UTC within functional units independent of their TCR-based lineage. These
results add significantly to our understanding of UTC biology and have direct clinical implications.
We hope that our data will guide targeted vaccination approaches and cell-based therapies to
optimize immune responses against pathogens and cancer.
Cadherin-13 (CDH13) is a member of the cadherin superfamily that lacks the typical transmembrane domain for classical cadherins and is instead attached to the cell membrane with a GPI-anchor. Over the years, numerous genome-wide association (GWA) studies have identified CDH13 as a risk factor for neurodevelopmental disorders, including attention- deficit/hyperactivity disorder (ADHD) and autism spectrum disorder. Further evidence using cultured cells and animal models has shown that CDH13 plays important roles in cell migration, neurite outgrowth and synaptic function of the central nervous system. Research in our laboratory demonstrated that the CDH13 deficiency resulted in increased cell density of serotonergic neurons of the dorsal raphe (DR) in developing and mature mouse brains as well as serotonergic hyperinnervation in the developing prefrontal cortex, one of the target areas of DR serotonergic neurons. In this study, the role of CDH13 was further explored using constitutive and serotonergic system-specific CDH13-deficient mouse models. Within the adult DR structure, the increased density of DR serotonergic neurons was found to be topographically restricted to the ventral and lateral-wing, but not dorsal, clusters of DR. Furthermore, serotonergic hyperinnervation was observed in the target region of DR serotonergic projection neurons in the lateral wings. Unexpectedly, these alterations were not observed in postnatal day 14 brains of CDH13-deficient mice. Additionally, behavioral assessments revealed cognitive deficits in terms of compromised learning and memory ability as well as impulsive-like behaviors in CDH13-deficient mice, indicating that the absence of CDH13 in the serotonergic system alone was sufficient to impact cognitive functions and behavioral competency. Lastly, in order to examine the organization of serotonergic circuitries systematically and to tackle limitations of conventional immunofluorescence, a pipeline of the whole-mount immunostaining in combination with the iDISCO+ based rapid tissue clearing techniques was established. This will facilitate future research of brain neurotransmitter systems at circuitry and/or whole-brain levels and provide an excellent alternative for visualizing detailed and comprehensive information about a biological system in its original space. In summary, this study provided new evidence of CDH13’s contribution to proper brain development and cognitive function in mice, thereby offering insights into further advancement of therapeutic approaches for neurodevelopmental disorders.
Diarrheal diseases are a major cause of death in developing countries. Vaccinating against the causative pathogens could reduce mortality and morbidity in these countries. Unfortunately, only for some of the most common enteral pathogens are vaccines available. Some of these available vaccines have limitations in terms of effectiveness and duration of protection. There is therefore an urgent need to develop new vaccine strategies that can generate protection against enteral pathogens.
The presence of all-trans retinoic acid (ATRA) during lymphocyte maturation is known to imprint a phenotype on lymphocytes that enables them to home to the intestines. Additionally, ATRA is known to play a role in B cell class switch to IgA, which is the dominant immunoglobulin in the intestines.
The aim of this study was therefore to investigate whether the addition of all-trans retinoic acid (ATRA) or a retinoic acid receptor agonist (AM80) to a parenteral vaccination could provide protection at the intestinal mucosa against enteric pathogens.
C57BL/6 mice received s.c. priming and boosting immunizations with Ovalbumin followed by several s.c. injections with either ATRA, AM80 or the respective solvent as control substance. Feces, serum, saliva and vaginal lavage samples were collected and analyzed by ELISA for detection and relative quantification of antigen-specific antibodies. B cell populations in the draining lymph nodes were investigated after immunization using flow-cytometry. Antigen-specific antibodies producing cells were visualized in the small intestine of vaccinated animals using two-photon microscopy.
Animals that were vaccinated and were exposed to AM80, and to a lesser extent ATRA exposed mice, had higher serum, fecal, saliva and vaginal lavage antigen-specific IgA titers when compared to animals that were vaccinated but did not receive ATRA/AM80. Antigen-specific IgG titers were not altered in any of the investigated tissues. In the draining lymph nodes, IgA+ and IgG+ B cells were increased after vaccination and AM80 exposure at several time points within 14 days after vaccination. Antigen-specific IgA+ cells were found in the small intestine of immunized and AM80-exposed but not control substance-exposed mice.
These results suggest that the addition of ATRA or AM80 to parenteral vaccine formulations increases the abundance of antigen-specific antibodies at mucosal surfaces, and therefore have the potential to generate protective antibody titers at those mucosal surfaces.